PARP Inhibitors Do Not Significantly Increase Risk for Secondary Hematologic Malignancy

Web Exclusives - Ovarian Cancer

The risk for secondary hematologic malignancies is not increased significantly in women with advanced ovarian cancer who are treated with poly (ADP-ribose) polymerase (PARP) inhibitor maintenance or as first-line treatment.

In a combined meta-analysis of 7 phase 3 randomized controlled trials of women with advanced ovarian cancer, the overall incidence of secondary hematologic malignancies was 0.80% in the women randomized to PARP inhibitors as maintenance compared with 0.47% in controls (risk ratio [RR], 1.45; 95% confidence interval [CI], 0.68-3.07; P = .34).

The data were reported by Thura W. Htut, MBBS, MRCP, Haematology Fellow, Aberdeen Royal Infirmary, Scotland, UK, and colleagues in poster format at the 2020 virtual scientific program of the American Society of Clinical Oncology.

A total of 4445 patients were included from the ARIEL3, ENGOT-OV16/NOVA, and SOLO-2 clinical trials in which PARP inhibitors were studied in the treatment of recurrent ovarian cancer, and VELIA, PRIMA, SOLO-1, and PAOLA-1 clinical trials in which PARP inhibitors were studied as first-line treatment. Treatment regimens in the study arm were olaparib (Lynparza), niraparib (Zejula), rucaparib (Rubraca), veliparib, or olaparib plus bevacizumab (Avastin), while the control arm consisted of placebo or bevacizumab. Randomization was 2:1 in all studies.

In patients with newly diagnosed ovarian cancer (N = 3044), the incidence of a secondary hematologic malignancy was 0.59% in the group randomized to PARP inhibitors compared with 0.09% in the control group. Despite a numeric trend toward increased incidence in patients receiving PARP inhibitors, the difference was not statistically significant (RR, 2.7; 95% CI, 0.7-10.37; P = .15).

In women with recurrent ovarian cancer (N = 1401), secondary hematologic malignancy rates were identical, developing in 1.28% of the PARP inhibitor and control arms (RR, 0.96; 95% CI, 0.38-2.46; P = .94).

Estimates were derived for patients treated with olaparib or niraparib within the PARP inhibitor group. For those treated with olaparib, the rate of secondary hematologic malignancy was 1.3% compared with 1% in the controls (RR, 1.24; 95% CI, 0.46-3.31; P = .67). Among patients assigned to niraparib, the rates were identical, with 0.47% developing a secondary hematologic malignancy in both the niraparib and control groups (RR, 1.28; 95% CI, 0.30-5.45; P = .74).

Related Items
ASCO Guidelines Support PARP Inhibitor Use in Maintenance and Recurrent Setting of Advanced Ovarian Cancer
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling
Web Exclusives published on October 13, 2020 in Ovarian Cancer
Phase 2 OVARIO Update: Promising Survival Rates in Patients with Advanced Ovarian Cancer Treated with Niraparib plus Bevacizumab Maintenance
Web Exclusives published on September 15, 2020 in Ovarian Cancer
No Difference in PFS Between Platinum-Based Chemotherapy and Olaparib in Women with Platinum-Sensitive Ovarian Cancer
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Safety of Approved Rucaparib Starting Dose Confirmed from Pooled Analysis
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Phase 3 Study to Investigate Anti–PD-1 Antibody in the Treatment of High-Grade Ovarian Cancer
Web Exclusives published on September 15, 2020 in Ovarian Cancer
Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer
Web Exclusives published on July 28, 2020 in Ovarian Cancer
Olaparib Extends Survival by >1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation
Web Exclusives published on July 28, 2020 in Ovarian Cancer
Last modified: September 15, 2020